| | Title | Authors / Editors | Date |
|
unige:111093 |
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis |
Bone, Henry G; Cosman, Felicia; Miller, Paul D; Williams, Gregory C; ... Saag, Kenneth G |
2018 |
|
unige:107112 |
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab |
Cosman, Felicia; Crittenden, Daria B; Ferrari, Serge Livio; Khan, Aliya; ... Grauer, Andreas |
2018 |
|
unige:28838 |
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective |
Boonen, Steven; Ferrari, Serge Livio; Miller, Paul D; Eriksen, Erik F; ... Cosman, Felicia |
2012 |
|
unige:111095 |
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome |
Cosman, Felicia; Crittenden, Daria B; Ferrari, Serge Livio; Lewiecki, E Michael; ... Grauer, Andreas |
2018 |
|
unige:89797 |
Romosozumab Treatment in Postmenopausal Women with Osteoporosis |
Cosman, Felicia; Crittenden, Daria B.; Adachi, Jonathan D.; Binkley, Neil; ... Grauer, Andreas |
2016 |
|
unige:143606 |
T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial |
Cosman, Felicia; Lewiecki, E Michael; Ebeling, Peter R; Hesse, Eric; ... Ferrari, Serge Livio |
2020 |
Cosman, Felicia
add all
remove all
